PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 24-week liver biopsy results in four subjects from AROAAT2002, an open-label Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback